A screen of ~12,800 small molecules identified homoharringtonine (HHT), an FDA-approved drug for treating chronic myeloid leukemia, as a VHL-synthetic lethal agent in ccRCC. The gene discussed is VHL; the disease is nonpapillary renal cell carcinoma.